Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2018-07-11 Capital/Financing Update
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
STADA Arzneimittel AG: Announcement of the results of the Tender Offer regarding the STADA-Bond 2015/2022:
Capital/Financing Update Classification · 99% confidence The document is an announcement dated July 11, 2018, from STADA Arzneimittel AG regarding the results of a Tender Offer for its outstanding EUR 300,000,000 1.750% Notes due 2022. It details the aggregate principal amount tendered (EUR 15,656,000) and confirms acceptance, along with the expected payment date. This is a specific corporate action related to debt instruments and financing structure, not a general financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It fits best under 'Capital/Financing Update' (CAP) as it concerns the repurchase/cancellation of outstanding notes, which is a capital structure activity. It is not a share issue (SHA) or a transaction in own shares (POS) as it deals with bonds/notes, not equity shares.
2018-07-11 English
STADA Arzneimittel AG: NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.
Regulatory Filings Classification · 99% confidence The document is a short announcement (4809 characters) published via DGAP-News, explicitly stating it is an 'Investor News' and detailing actions related to STADA's Euro bond (2015/2022). Specifically, it announces the invitation to a noteholders' meeting regarding the appointment of a common representative and the launch of a Tender Offer to repurchase these notes. This involves changes to debt instruments and capital structure management, but it is not a full financial report (10-K, IR) or a standard earnings release (ER). Since it announces a specific corporate action related to financing/capital structure (bond modification and tender offer), it fits best under Capital/Financing Update (CAP). It is an announcement of an action, not the final legal document itself, but CAP is more specific than the general fallback RNS.
2018-06-29 English
STADA Arzneimittel AG: Strategic expansion of OTC portfolio continues - STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica
M&A Activity Classification · 99% confidence The document is a news release dated June 28, 2018, announcing that STADA Arzneimittel AG has acquired the EMEA rights to the anti-dandruff brand Nizoral from Janssen Pharmaceutica. It details the strategic rationale, sales figures, and brand portfolio expansion. This type of announcement, which details a significant corporate transaction (M&A activity), is best classified under the Merger/Acquisition Activity category (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a general regulatory announcement (RNS), as it specifically concerns a takeover/acquisition component.
2018-06-28 English
Datum:19.06.2018
Management Reports Classification · 100% confidence The document is titled 'Lagebericht für das Geschäftsjahr 2017' (Management Report for the 2017 Financial Year) for STADA Arzneimittel AG. It contains detailed financial performance analysis, segment reporting, economic environment analysis, and management's discussion of results. This is a core component of an annual report. While it is a segment of the full report, it represents the 'Management Report' (Lagebericht) section, which is a primary component of the 10-K equivalent in Germany. Given the length and depth of the content, it is classified as an Annual Report.
2018-06-19 German
STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022
Capital/Financing Update Classification · 98% confidence The document is a news release from STADA Arzneimittel AG dated June 8, 2018, announcing a 'Consent Solicitation' for its STADA Euro bond 2015/2022. This action involves seeking approval from noteholders for modifications related to security arrangements for a majority shareholder's financing. It also mentions a related tender offer for cash. This type of announcement, dealing with debt instruments, financing arrangements, and potential restructuring/amendments, falls under Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific corporate finance action.
2018-06-08 English
STADA Arzneimittel AG: Annual General Meeting approves agenda items with a large majority
AGM Information Classification · 99% confidence The document explicitly mentions 'Annual General Meeting' (AGM) multiple times, stating that shareholders approved agenda items at the meeting held on June 6, 2018. It provides details about the meeting and directs the reader to the website for voting results. This content directly relates to the AGM proceedings. Therefore, the appropriate classification is AGM Information (AGM-R). The document is an announcement summarizing the outcome of the AGM, which fits the AGM-R definition.
2018-06-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.